Kamada (KMDA) to Release Earnings on Monday

Kamada (NASDAQ:KMDA) is expected to be releasing its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect Kamada to post earnings of $0.10 per share and revenue of $154.2050 million for the quarter. Kamada has set its FY 2025 guidance at EPS.Interested persons are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 10, 2025 at 8:30 AM ET.

Kamada (NASDAQ:KMDA) last announced its earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.04. Kamada had a return on equity of 7.41% and a net margin of 11.22%.The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $158.59 million. On average, analysts expect Kamada to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kamada Stock Down 3.2%

Shares of NASDAQ:KMDA opened at $6.67 on Wednesday. The business has a 50 day moving average price of $6.90 and a 200 day moving average price of $7.07. Kamada has a twelve month low of $5.54 and a twelve month high of $9.15. The company has a market cap of $383.56 million, a price-to-earnings ratio of 19.62, a PEG ratio of 0.70 and a beta of 0.84.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “buy (b-)” rating on shares of Kamada in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $13.00.

Institutional Trading of Kamada

A number of hedge funds have recently modified their holdings of KMDA. Cubist Systematic Strategies LLC bought a new position in shares of Kamada during the 1st quarter worth approximately $206,000. NewEdge Advisors LLC lifted its position in shares of Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock worth $341,000 after buying an additional 28,165 shares during the period. Goldman Sachs Group Inc. bought a new position in shares of Kamada during the 1st quarter worth approximately $497,000. Jane Street Group LLC bought a new position in shares of Kamada during the 1st quarter worth approximately $582,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Kamada during the 2nd quarter worth approximately $472,000. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.